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Abstract 
Background 
The clinical condition of dementia is now recognised as a diagnosis that can only be applied 
too late in the disease process to be useful for therapeutic approaches centring on disease 
modification. As a result, in recent years increasing attention has been given to mild cognitive 
impairment (MCI) and the diagnosis of prodromal dementia. This paper reviews the evidence 
for the clinical presentation of prodromal dementia with Lewy bodies (DLB). 
 
Methods 
A MEDLINE search was carried out to identify papers with original data on the prodromal 
presentation of DLB. 
 
Results 
In MCI cohorts that progress to dementia, the proportion diagnosed with DLB is similar to 
that reported in dementia cohorts. Prodromal DLB may present as any MCI subtype, though 
visuospatial and executive domains may be most commonly affected. REM sleep behaviour 
disorder (RBD), autonomic symptoms, hyposmia, hallucinations and motor symptoms appear 
to be more common in prodromal DLB than prodromal Alzheimer’s disease. Some of these 
symptoms can precede the diagnosis of DLB by several years. 
There has been little research into the use of biomarkers in prodromal DLB, though in RBD 
cohorts clinical and imaging biomarkers have been associated with the development of DLB.  
 
Conclusions 
The evidence available suggests that prodromal DLB may be differentiated from other 
dementia prodromes in most cases. Further research is needed to confirm this, and to assess 
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the utility of biomarkers such as 
123
I-FP-CIT and 
131
I-MIBG imaging.
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Introduction 
 
The clinical condition of dementia, by definition a global cognitive decline with functional 
impairment, is now recognised as a diagnosis that can only be applied too late in the disease 
process to be useful for current and future therapeutic approaches which centre on disease 
modification. As a result, in recent years increasing research attention has been given to mild 
cognitive impairment (MCI) and the diagnosis of prodromal dementia. Petersen et al. (1999) 
described MCI as an entity with clinical characteristics intermediate between dementia and 
healthy controls, and high rates of conversion to dementia (most commonly Alzheimer’s 
disease (AD), because of the amnestic weighting of the MCI definition). Later, the diagnosis 
was refined to subcategorise MCI into amnestic and non-amnestic MCI (aMCI and naMCI 
respectively), depending on whether memory was affected or not (Petersen et al., 2001, 
Winblad et al., 2004). aMCI was hypothesised to precede AD or vascular dementia, whereas 
naMCI was felt more likely to precede dementia with Lewy bodies (DLB), vascular dementia 
or frontotemporal dementia (Petersen, 2004). 
More recently, criteria for the diagnosis of MCI due to AD (Albert et al., 2011) and 
prodromal AD (Dubois et al., 2010) have been put forward. These diagnostic criteria are 
similar to previous descriptions of aMCI but also include validated disease biomarkers 
indicative of brain amyloid deposition and/or neuronal injury.  
 
The diagnosis of prodromal dementia has gained prominence following disappointing results 
in recent trials of anti-amyloid therapies and the hypothesis that such treatments may only be 
successful in the earliest stages of the disease (Aisen et al., 2013). AD, the most common 
type of dementia, has received significant attention in this regard. There are a wide variety of 
other causes of dementia, with vascular dementia, DLB and frontotemporal dementia being 
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among the most common. Less common subtypes account for a significant proportion of 
dementia cases, particularly in those under 65 years old (Harvey et al., 2003). Huntington’s 
disease has demonstrated a long prodromal phase that has been characterised in recent 
longitudinal studies (Paulsen et al., 2008, Tabrizi et al., 2012). 
 
DLB is the second most common type of neurodegenerative dementia after AD, accounting 
for at least 4.2% of all diagnosed dementias in the community and 7.5% of those in secondary 
care (Vann Jones and O'Brien, 2014). There are validated consensus criteria for the clinical 
diagnosis of DLB (McKeith et al., 2005). These display high positive predictive value for the 
post-mortem neuropathological classification of intermediate- or high-likelihood DLB 
(Fujishiro et al., 2008). DLB requires different management from AD, most notably the 
avoidance of antipsychotic medications (Ballard et al., 1998).  
 
The existence of a prodromal phase of DLB is to be expected, given the insidiously 
progressive nature of the disorder, as with AD. It may also be expected that prodromal DLB 
should display some of the features characteristic of established DLB (Table 1) (McKeith et 
al., 2005, Troster, 2008). The identification of a DLB prodrome would enable investigation 
of the early pathophysiology of DLB and the development of treatments to interrupt these 
pathophysiological processes. Prodromal DLB may require different management from other 
dementia prodromes. For example, DLB may potentially be more responsive to 
cholinesterase inhibition in its prodromal phase, given the early and widespread cholinergic 
losses seen in DLB compared with AD (Tiraboschi et al., 2002). 
In this paper we review the evidence to determine if DLB has a characteristic prodromal 
phase that may allow its differentiation from other dementia prodromes.  
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Method 
A MEDLINE (Web of Knowledge; 1950-present) search was carried out in October 2013. 
The search algorithm used was: [“MCI” OR “mild cognitive impairment” OR “mild 
dementia” OR “prodrom*”] AND [“Lewy”].  
378 English-language results were found. Titles and abstracts were then screened by two 
reviewers (PD and AT). Case studies were excluded. In longitudinal cohorts where the same 
outcomes had been reported at different time points only the most recent results were 
included. A total of 54 relevant papers were identified.  After reading these papers, it was 
apparent that the original search did not find a significant number of relevant papers 
investigating rapid eye movement sleep behaviour disorder (RBD) as a prodrome of DLB. 
A second search was carried out using the terms [“RBD” OR “REM sleep behaviour 
disorder” OR “rapid eye movement sleep behaviour disorder”] AND [“Lewy”]. Of 108 
further results, 15 papers of interest were identified. 
After further assessment, 29 papers were found to contain original data on prodromal DLB. A 
further paper was found after searching the bibliographies of these papers (Postuma et al., 
2011). 
 
 
 
Results 
Epidemiological studies of rates of conversion from MCI to DLB 
Three studies have prospectively followed-up patients with MCI for the development of 
DLB. In a cohort of 581 75 year-olds (440 cognitively healthy, 48 with aMCI and 93 with 
naMCI) followed up for 30 months, possible DLB was found in 10 cases, all of whom also 
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fulfilled clinical criteria for possible or probable AD (Fischer et al., 2007). At baseline 4 were 
cognitively healthy, 2 had aMCI, and 4 had naMCI. In another group of 133 patients with 
MCI followed up for 6 years, 53.4% developed dementia and 5.6% (4/71) of these dementia 
cases were diagnosed as DLB (Palmqvist et al., 2012). One study that followed-up 170 
consecutive cases of MCI at a memory clinic found high rates of DLB (22% of dementia 
cases were probable DLB, 6% were possible DLB) (Bombois et al., 2008). The heterogeneity 
of these results can at least partly be attributed to the recruitment of participants, with the 
highest proportions of DLB found in a study recruiting from a tertiary referral centre 
(Bombois et al., 2008), and the lowest in a study that recruited most patients from primary 
care units (Palmqvist et al., 2012). 
 
In a post-mortem study of 134 patients who died with a diagnosis of MCI, 8 (6%) had cortical 
Lewy bodies (LBs); 5 of these 8 in the absence of vascular or AD pathology. A further 10% 
had nigral or limbic LBs (Schneider et al., 2009). Saito and Murayama (2007) found  that, of 
33 MCI cases showing degenerative pathology post-mortem, 6 (18%) had LB pathology, with 
half of these showing only DLB type changes. Another small study of an aMCI group found 
that 1/15 cases had transitional LB pathology post-mortem, along with some AD pathology 
(Petersen et al., 2006). 
 
 
Clinical studies of prodromal DLB 
Three studies (Auning et al., 2011, Chiba et al., 2012, Fujishiro et al., 2013) have asked 
patients with DLB and/or their carers to retrospectively report on the early symptoms of DLB 
(Table 2). 
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[Insert Table 2 Here] 
 
Auning et al. (2011) interviewed carers of patients newly diagnosed with mild DLB about the 
presenting symptoms of DLB (MMSE>20; n=61). Visual hallucinations (44%), gait problems 
(28%), tremor/stiffness (25%) and a tendency to fall (13%) were significantly more common 
in DLB compared with an AD control group, whereas memory problems were significantly 
less common. Fluctuating cognition was not offered as an option for presenting symptom. 
Carers did have the opportunity to report symptoms not on the preselected list, but any other 
reported symptoms were infrequent (<10%). 
 
Chiba et al. (2012) asked patients and carers to fill in a survey of pre-defined symptoms 
without any additional instruction. They looked at the temporal onset of symptoms relative to 
memory loss. This was to allow comparison of DLB (n=34) and AD (n=32), both of which 
are associated with progressive memory impairment. 
The most common symptoms present in the same year as the onset of memory loss were 
sleep rhythm change (62%), crying/shouting in sleep (62%), anosmia/hyposmia (41%), 
constipation (47%) and limb movements in sleep (35%) (Table 2). 
Of those symptoms that were more common in DLB than AD, the earliest to develop were 
constipation (mean = 9.4 years before memory impairment); crying/shouting during sleep 
(4.9 years); limb movements during sleep (3.9 years); anosmia/hyposmia (2.9 years) and 
nightmares (2.5 years). 
The three symptoms taken to be most representative of DLB (due to high prevalence in DLB 
and relatively low prevalence in AD/controls) were crying/shouting during sleep, 
constipation and anosmia/hyposmia. One or more of these symptoms differentiated DLB 
from AD with a sensitivity of 0.71 and a specificity of 0.81. Increasing the threshold to two 
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or more symptoms resulted in a decrease of sensitivity to 0.38 but an increase in specificity to 
0.97. The questionnaire did not enquire about parkinsonism, hallucinations or fluctuations. 
 
The same group later assessed the presence and time of onset of core features and eight 
symptoms of Lewy body disease in 90 patients with probable DLB (Fujishiro et al., 2013). 
There was no comparison group. As with the previous study, the presence of each symptom 
at the onset of memory loss was recorded. This study found comparable rates of constipation, 
anosmia/hyposmia, RBD, depression and orthostatic dizziness to their previous study (Table 
2). Lower rates of urinary incontinence were found (8%), and syncope was relatively rare 
(7%).  
This study confirmed that constipation, anosmia and RBD often precede the onset of memory 
loss by several years. Visual hallucinations and extrapyramidal symptoms each were present 
in around one third of individuals at the onset of memory loss, though on average these 
symptoms developed 1.5 years after memory loss. 
 
 
Post-mortem studies of prodromal symptoms of DLB 
Some post-mortem studies of established DLB have retrospectively assessed the 
chronological development of symptoms. Ferman et al. (2011) examined 98 patients with 
intermediate-high likelihood of DLB on post-mortem examination who had been part of a 
longitudinal study.  On average, RBD preceded dementia by 6 years (with wide variation 
(SD=12 years), possibly reflecting some cases with very early onset RBD). Conversely visual 
hallucinations and parkinsonism followed the estimated dementia onset by an average of 2.6 
and 1.8 years respectively. Another Mayo Clinic post-mortem study examined 52 patients 
diagnosed during life with probable or possible DLB (Fujishiro et al., 2008). The authors 
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remarked that “RBD antedated the diagnosis of DLB in almost all cases in which RBD was 
noted”, whereas the presence of notable visual hallucinations followed the development of 
dementia by an average of 2.8 years. 
 
Both of the above studies recruited subjects when they had already been diagnosed with 
dementia and prospectively collected information through regular clinical and 
neuropsychiatric assessments. Two further studies specifically recruited non-demented 
subjects for prospective follow-up. These studies reported a different pattern of symptom 
development in prodromal DLB. 
 
Jicha et al. (2010) enrolled cognitively normal patients for regular clinical follow-up and 
brain donation following death. Nine patients with neocortical DLB post-mortem and no 
significant AD or vascular pathology had an identified MCI phase during their illness. This 
group was compared with 12 patients with a post-mortem diagnosis of AD. 
None of the AD-MCI group displayed parkinsonism, cognitive fluctuations or psychiatric 
symptoms (hallucinations/delusions/paranoia) during the MCI phase. 8/9 MCI-DLB 
demonstrated at least one of these features concurrent with the MCI diagnosis (parkinsonism 
n=5; fluctuations n=3; psychiatric symptom n=4).  
DLB-MCI was associated with significant memory impairment, but the group performed 
better on immediate recall than AD-MCI. They were worse on phonemic fluency and tended 
toward being worse at trail-making, but were better at the Boston Naming Test. It must be 
noted that, due to the strict inclusion criteria, these findings only represent the MCI phase of 
patients with later neocortical LB deposition (i.e. a subset of all those who have DLB, some 
of whom will not have cortical involvement) and without significant vascular or AD 
pathology. 
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In a similar study, Molano et al. (2010) identified 8 patients from their research databases 
that had been prospectively followed up after a diagnosis of MCI, and later were found have 
LB disease post-mortem (limbic- or neocortical-predominant). In the year of MCI diagnosis, 
or preceding this, 5 displayed parkinsonism and 3 had visual hallucinations, whereas none 
displayed fluctuations. RBD was present in 7 cases at the diagnosis of MCI, preceding it by 
up to 47 years.  
7 cases developed dementia before death. Of these 5 had parkinsonism, 5 had hallucinations 
and 2 had fluctuations before the development of dementia. 
The patients had a variety of MCI subtypes. Attention/executive function (n=6) and 
visuospatial function (n=6) were the cognitive domains most commonly affected.  
 
 
Imaging findings in Prodromal DLB 
Six studies have performed imaging in MCI subjects that later developed DLB. 
In the study discussed above (Molano et al., 2010), 3 cases had serial MRI. Compared with 
previously published data, hippocampal volumes at time of MCI and rate of hippocampal 
atrophy were within the range of cognitively normal subjects. 
 
In a group of 170 patients with MCI, baseline subcortical hyperintensities on MRI were 
associated with an increased risk of developing mixed or vascular dementia, but not DLB or 
other dementia subtypes (Bombois et al., 2008). 
 
One study has performed PET dopamine terminal imaging on subjects with MCI with follow-
up for the development of DLB (Albin et al., 2013). Of 27 MCI subjects, two had markedly 
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reduced striatal 
11
C-dihydrotetrobenazine binding. Both developed dementia at follow-up; 
one was classified as DLB, the other as frontotemporal dementia. However, 3/25 MCI 
subjects with normal 
11
C-dihydrotetrabenazine scans also developed DLB.  
 
Clerici et al. (2009) performed 
18
F-FDG PET on 16 patients with single domain aMCI and 14 
patients with naMCI with executive dysfunction. These were compared with controls that 
were undergoing PET scans for cancer restaging. 
Of those who completed follow-up, 1/14 aMCI and 5/12 naMCI developed DLB. In a voxel-
based analysis, the naMCI who developed DLB had heterogeneous patterns of 
hypometabolism compared to controls. The inferior and mesial frontal; anterior and posterior 
cingulate; superior temporal and inferior parietal areas were most frequently involved. 
Frontal hypometabolism may have been expected, given that executive dysfunction was one 
of the inclusion criteria for the naMCI group. This may not be representative of all prodromal 
DLB. 
Pardo et al. (2010) followed 19 army veterans with MCI for 3 years following baseline FDG-
PET scans. Two developed DLB; both had an ‘AD-like’ pattern of hypometabolism 
(hypometabolism in medial parietal and lateral parietal regions) on visual inspection. Neither 
displayed occipital hypometabolism. 
 
Another study performed MR spectroscopy, diffusion weighted imaging (DWI) and perfusion 
imaging on 119 patients with MCI (Fayed et al., 2008). After follow-up subjects could be 
classified as AD (including mixed dementia, n=49); Lewy body dementia (LBD) (n=5; 
criteria not stated); MCI due to vascular disease (n=15); MCI due to depression (n=22); or 
MCI due to AD (n=28).  
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There were no differences between LBD and the other groups in baseline spectroscopy or 
perfusion findings. 
On DWI in the right hippocampus, the LBD group higher baseline Apparent Diffusion 
Coefficient (ADC) values compared with the 3 MCI groups, indicating greater white matter 
disruption. The difference between LBD and AD approached significance (p=0.08). Values in 
the AD/mixed dementia group did not differ from the MCI groups. Baseline characteristics 
were not provided, so the findings could be due to differences between groups at baseline 
(e.g. age or severity of cognitive impairment). 
 
 
REM Sleep Behaviour Disorder 
RBD is associated with high rates of conversion to dementia. Longitudinal studies have 
estimated that over half of patients with RBD go on to develop a neurodegenerative disorder 
which is nearly always a synucleinopathy (e.g. Parkinson’s disease (PD), Parkinson’s disease 
dementia, DLB, multi-system atrophy) if followed-up for more than a decade, rising to up to 
93% if followed-up over longer periods (Postuma et al., 2009, Iranzo et al., 2013, Schenck et 
al., 2013). In these studies, 14-39% of those who developed a neurodegenerative disorder 
were diagnosed with DLB. 
 
Studies specifically looking at DLB with RBD have confirmed that RBD tends to precede 
cognitive symptoms by several years (Boeve et al., 1998, Boeve et al., 2003). In some cases 
the gap is over 25 years (Claassen et al., 2010). Core symptoms may develop earlier in DLB 
patients with RBD than those without RBD (Dugger et al., 2012). 
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Imaging in RBD to predict the development of DLB 
Dang-Vu et al. (2012) performed 
99m
Tc-ECD SPECT perfusion scanning on 20 patients with 
RBD who did not have dementia (though 13 had MCI), and compared these to 10 healthy 
controls. After an average follow-up of 3 years, 5 RBD subjects developed DLB (criteria not 
stated) and 5 PD. All those who developed DLB had an initial diagnosis of MCI. 
The PD/DLB group had increased baseline hippocampal regional cerebral blood-flow (rCBF) 
compared to the RBD group that did not develop neurodegenerative disease. The 5 DLB 
patients had increased hippocampal rCBF compared with controls. There were no significant 
differences between the PD and DLB groups. The PD/DLB group was on average 4.8 years 
older than the RBD subjects that did not develop disease. 
 
Iranzo et al. (2010) performed striatal dopamine terminal binding of 
123
I-FP-CIT and 
transcranial echosonography of the substantia nigra in 43 patients with RBD. Eight patients 
later developed neurodegenerative disease (5 PD, 2 DLB and 1 multi-system atrophy), all of 
whom had at least one abnormal imaging finding. 30% of those with an abnormal finding 
developed a neurodegenerative disease at 2.5 years, compared with 0% of those with 2 
normal scans. Both DLB cases displayed substantia nigra hyperechogenicity and one had 
reduced striatal 
123
I-FP-CIT uptake at baseline. 
 
Other biomarkers in RBD to predict the development of DLB 
Postuma and colleagues commenced a longitudinal study of RBD in 2004. After several years 
they have been able to identify baseline symptoms and signs that were associated with the 
development of neurodegenerative disease. In their latest report, 32 of 91 RBD subjects in 
their cohort had developed neurodegenerative disease (11 probable DLB, 4 possible DLB, 17 
parkinsonism) (Postuma et al., 2013). 
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The RBD group that developed neurodegenerative disease reported greater baseline levels of 
urinary dysfunction, erectile dysfunction and constipation than controls (Postuma et al., 
2013). They did not report more symptoms of orthostatic hypotension, but did have a greater 
postural drop in blood pressure. These abnormalities were present four or more years before 
the development of neurodegenerative disease. The results of the RBD without 
neurodegenerative disease group were intermediate between the controls and the disease 
group, possibly reflecting that some of this group were in the process of developing a 
neurodegenerative disease. Baseline postural hypotension and urinary dysfunction were 
significantly more common in the disease than the non-disease RBD group. ECG measures of 
autonomic dysfunction did not predict the development of neurodegenerative disease in RBD 
(Postuma et al., 2010). 
 
Motor abnormalities assessed by the UPDRS, the alternate-tap test, the Purdue Pegboard and 
the timed up-and-go were all found to be abnormal in DLB three or more years before the 
diagnosis of dementia (Postuma et al., 2012). These tests appeared to be abnormal for longer 
periods before the development of DLB than PD. 
 
Patients that developed DLB or PD dementia had abnormal baseline colour vision and 
olfactory function, assessed using the Farnsworth-Munsell-100-Hue and University of 
Pennsylvania Smell Identification tests respectively (Postuma et al., 2011). These 
abnormalities were present at the first assessment, up to 5 years before the development of 
dementia. Those with both abnormal olfaction and colour vision had an estimated disease-
free survival (i.e. no DLB, PD dementia or PD) of 18%, compared with 82% of those with 
normal function on both tests. 
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In general, each of the abnormalities discussed above had high specificity but low sensitivity 
in identifying those with RBD that would go on to develop neurodegenerative disease. They 
were present some years before the diagnosis of disease and tended to progress slowly. 
 
 
Discussion 
Clinical presentation of prodromal DLB 
The above evidence suggests that DLB can be preceded by an MCI phase before the 
development of dementia. Two studies that followed up participants with MCI for the 
development of DLB (Fischer et al., 2007, Palmqvist et al., 2012), reported figures similar to 
reported rates of DLB in clinically diagnosed dementia samples (Vann Jones and O'Brien, 
2014); though rates varied greatly between studies, most likely due to recruitment from 
different clinical populations. 
Although the data available are limited, the pattern of symptoms in prodromal DLB appears 
to differ from that of prodromal AD. Particular symptoms that are more frequent in 
prodromal DLB include RBD, autonomic dysfunction (including constipation and orthostatic 
dizziness), hyposmia, visual hallucinations and motor symptoms. Even without including 
core symptoms, prodromal DLB may be discriminated from prodromal AD reasonable 
sensitivity and specificity (Chiba et al., 2012). The earliest symptoms of DLB are 
constipation, RBD and hyposmia. RBD has been demonstrated to precede DLB by decades in 
some cases. Table 3 shows approximate temporal relationships between symptoms in 
prodromal DLB from the evidence currently available. The order of symptom development is 
similar to that reported in PD (Gaenslen et al., 2011). 
 
[Insert Table 3 here] 
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Prodromal DLB can present with either amnestic or nonamnestic cognitive impairment 
(Fischer et al., 2007, Clerici et al., 2009, Molano et al., 2010), though visuospatial and 
executive function may be particularly likely to be affected (Molano et al., 2010). This is 
supported by findings in a recent study comparing neuropsychological measures at initial 
presentation (including MCI and mild dementia cases) (Yoshizawa et al., 2013). Those with 
‘pure’ DLB pathology at post mortem had greater visuospatial impairment and less memory 
impairment at initial assessment compared to ‘pure’ AD or mixed DLB+AD pathology 
groups. 
 
There is conflicting evidence on when the core features of DLB develop. Two longitudinal 
post-mortem cohorts that recruited subjects with dementia found that core features developed 
after the onset of dementia (Fujishiro et al., 2008, Ferman et al., 2011). Conversely, two 
longitudinal post-mortem studies that recruited before the onset of dementia (Jicha et al., 
2010, Molano et al., 2010) and two retrospective interview studies (Auning et al., 2011, 
Fujishiro et al., 2013) found that core symptoms commonly develop before the onset of 
dementia.  
These studies differed greatly in design and selection criteria, which may account for the 
differences in findings. Duration of dementia before death was notably different between 
some of the studies (≤4 years in Molano et al. (2010) v. 8-10 years on average in the two 
cohorts that recruited dementia patients (Fujishiro et al., 2008, Ferman et al., 2011)). This 
suggests that the studies may have recruited cohorts that were not clinically similar, or that 
diagnostic thresholds were different between the studies. 
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From this evidence, it appears that most cases of prodromal DLB will display clinical and 
neuropsychological characteristics similar to established DLB. The exact proportion of cases 
that conform to this phenotype remains to be established. In those cases that do not, other 
biomarkers may be needed to identify prodromal DLB.  
 
Biomarkers of prodromal DLB  
There has been little investigation into the use of imaging and other biomarkers to identify 
prodromal DLB. Indeed, we did not find any studies that investigated CSF biomarkers in 
prodromal DLB. Autonomic symptoms are common in prodromal DLB (Chiba et al., 2012); 
objective biomarkers of autonomic function such as postural hypotension could potentially be 
useful in the diagnosis of prodromal DLB. 
 
Dopamine terminal imaging can be abnormal in mild DLB in the absence clinical features of 
parkinsonism, suggesting that it may have a role in identifying prodromal DLB (Auning et 
al., 2011, Siepel et al., 2013). The only paper to investigate this (Albin et al., 2013) found 
that 1 of 2 MCI subjects with baseline striatal dopaminergic denervation later developed 
DLB. 3 other subjects that developed DLB had normal dopamine terminal scans in the MCI 
phase. The same authors had previously reported a case of rapid striatal dopaminergic 
denervation around the time of onset of DLB (Albin and Koeppe, 2006).  
With regards to other imaging modalities, raised hippocampal diffusivity on DWI compared 
with controls was found in one study, but this was not significantly greater than the 
prodromal AD group (Fayed et al., 2008). Surprisingly, the typical DLB pattern of occipital 
hypometabolism was not found in the few patients who had FDG-PET in the prodromal stage 
of the illness (Clerici et al., 2009, Pardo et al., 2010). 
20 
 
In summary, it appears that striatal dopaminergic innervation is abnormal in some, but not all 
patients with prodromal DLB; occipital hypometabolism may be a less sensitive marker of 
DLB in the prodromal phase. Further research is needed to evaluate the usefulness of these 
imaging modalities, and others known to be abnormal in established DLB, such as cardiac 
123
I-MIBG scintigraphy. 
 
RBD as a prodrome of DLB 
RBD patients represent a particular cohort at risk for developing DLB. Poor olfaction and 
colour vision; autonomic and motor dysfunction; reduced striatal dopaminergic innervation 
on SPECT; substantia nigra hyperechogenicity and increased hippocampal perfusion may all 
help to predict those with RBD that will go on to develop DLB or PD (Iranzo et al., 2010, 
Postuma et al., 2010, Postuma et al., 2011, Dang-Vu et al., 2012, Postuma et al., 2012, 
Postuma et al., 2013). None of these markers differentiate between those who will develop 
DLB from those who will develop PD. The evidence for these biomarkers is generally based 
on small DLB samples and none of the findings have been replicated. Findings in RBD 
groups may not be generalizable to the wider prodromal DLB population. 
 
Limitations 
With the exception of three retrospective symptom questionnaire studies (Auning et al., 2011, 
Chiba et al., 2012, Fujishiro et al., 2013), most of the evidence above relates to small groups 
of DLB patients. Few findings have been replicated. 
In general, the evidence is from clinical studies, without post-mortem verification of 
diagnosis. In some cases, this may have led to false positive or false negative results due to 
the misclassification of study subjects and such misclassification would in turn affect the 
apparent performance of biomarkers. Due to the heterogeneity of the data available, it is not 
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possible at this stage to combine the data or objectively compare the reliability of conflicting 
findings. This prevents us from objectively testing whether or not DLB has a distinct 
prodrome using this data. Longitudinal studies will be required, first to develop criteria for 
the prodrome of DLB, and then to test their validity.  
 
Conclusions 
The evidence available, though limited, suggests that DLB has an identifiable prodromal 
phase in most cases. It may be possible to differentiate prodromal DLB from prodromal AD 
based on the presence of core and suggestive features of DLB, autonomic dysfunction and 
other biomarkers. 
123
I-FP-CIT and 
131
I-MIBG SPECT findings are abnormal in established DLB. It remains to 
be ascertained at what point in the evolution of the disease these findings become abnormal, 
and if these scans will be clinically useful in the identification of prodromal DLB.  
Longitudinal studies are certainly needed to further characterise the clinical presentation of 
prodromal DLB and investigate the utility of biomarkers (including CSF biomarkers) in its 
identification. Interesting findings in RBD suggesting that olfactory, visual, autonomic and 
motor dysfunction; hippocampal hyperperfusion and substantia nigra hyperechogenicity may 
predict the development of DLB should be investigated in a ‘normal’ MCI group, not 
recruited in a specialist sleep disorders centre.  
 
Characterisation of the DLB prodrome is vital to enable the identification of DLB patients in 
the prodromal stage. This will facilitate research into the pathophysiology of prodromal DLB 
and the development of treatments aimed at halting or reversing these pathophysiological 
processes.  
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Table 1. Diagnostic features of DLB (adapted from McKeith et al. (2005)) 
 
Pattern of cognitive deficits – impairments of attention, executive and visuospatial function 
 
Core features – spontaneous parkinsonism, complex visual hallucinations, fluctuating cognition 
 
Suggestive features – REM sleep behaviour disorder (RBD), neuroleptic sensitivity, reduced dopamine transporter density in 
the striatum 
 
Supportive features – repeated falls/syncope, transient unexplained loss of consciousness, autonomic dysfunction, 
depression, hallucinations, delusions  
 
Imaging findings and other biomarkers – preservation of medial temporal lobe structures on structural imaging, reduced 
occipital perfusion, abnormal MIBG myocardial scintigraphy, EEG abnormalities 
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Table 2. The Prevalence of key symptoms in three clinical studies of prodromal DLB 
 
Auning et al. 2011 
(% of DLB patients with 
symptom as a presenting 
symptom; n=61) 
Chiba et al. 2012 
(% of DLB patients with each 
symptom in year of onset of 
memory loss; n=34) 
Fujishiro et al. 2013 
(% of DLB patients with each 
symptom in year of onset of 
memory loss; n=90) 
 
Cognitive Problems 
Memory 57 100 100 
Problem- solving 33   
Language 16   
Fluctuations    
 
Neuropsychiatric Symptoms 
Visual Hallucinations 44*  31 
Depression 34 24 19 
Anxiety  26*  
Lack of motivation  26  
 
Locomotor Symptoms 
Tremor/stiffness 25*   
Gait problems 27*   
Falls 13*   
Extrapyramidal signs   31 
 
Autonomic symptoms 
Constipation  47* 57 
Orthostatic dizziness  24* 18 
Urinary incontinence  27 8 
Increased salivation  21*  
 
Sleep symptoms 
Sleep rhythm change  62*  
Crying/shouting in sleep  62*  
Limb movements  35*  
Nightmares  27*  
RBD   46 
 
Other 
Anosmia/hyposmia  41* 38 
* = significantly more common than AD comparison group (no comparison group in Fujishiro et al.) 
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Table 3. Temporal order of symptom development in prodromal DLB 
 Very Early 
(developing before cognitive symptoms) 
Early 
(developing during MCI) 
Late 
(developing around the time of conversion to 
dementia or later) 
Symptoms RBD 
Constipation 
Hyposmia  
Depression 
Urinary dysfunction 
Erectile dysfunction 
Memory impairment 
Parkinsonian symptoms 
Visual hallucinations 
Anxiety 
Cognitive fluctuations 
 
Signs/neuropsychological 
findings/biomarkers 
Orthostatic hypotension/dizziness 
Minor motor abnormalities 
Impaired olfactory function 
Impaired colour vision 
 
Attention/executive dysfunction 
Visuospatial dysfunction 
Striatal dopaminergic denervation 
Substantia nigra hyperechogenicity 
Increased hippocampal rCBF 
Occipital hypometabolism 
Items in italics reflect evidence from cohorts with RBD at baseline that may not be applicable to prodromal DLB as a whole 
